Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects

Pharmacokinetics Clinical Trial

Official title:

A Randomized, Open, Parallel, Phase I Clinical Trial Comparing the Pharmacokinetics of MG-K10 Humanized Monoclonal Antibody in Healthy Adults

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06277284
• Other study ID #: MG-K10-I-002
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 23, 2023
• Est. completion date: April 2024

Study information

• Verified date: October 2023
• Source: Shanghai Mabgeek Biotech.Co.Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Research Topics A randomized, open-label, parallel-group, phase I clinical trial comparing the pharmacokinetics of MG-K10 humanized monoclonal antibody in healthy adults

Description:

Objectives of the Study Main objective: To compare the pharmacokinetics of MG-K10 after a single subcutaneous injection in healthy Chinese adult subjects. Secondary objectives: To evaluate other pharmacokinetic (PK) parameters of MG-K10 after a single subcutaneous injection; The safety and tolerability of a single subcutaneous injection of MG-K10 in healthy Chinese adult subjects were evaluated. To evaluate the immunogenicity of MG-K10 in healthy Chinese adult subjects. design: The number of cases in this trial was set as 30 cases in test drug (T) group and 30 cases in control drug (R) group, and a total of 60 subjects were enrolled.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: April 2024
• Est. primary completion date: January 26, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Participants signed the informed consent form before the study, and fully understood the content, process and possible adverse reactions of the study; Volunteer to participate and be able to complete the study in accordance with the protocol requirements.

2. Chinese healthy adult volunteers, male or female, aged 18-50 years old (inclusive) at the time of signing the informed consent form;

3. During the screening period, the body weight of male volunteers was =50 kg; Body weight of women =45 kg, and body weight of men and women must not exceed 80 kg (including 80 kg); Body mass index (BMI) in the range of 19.0-26.0kg/m2 (including the boundary value;

4. From the date of signing the informed consent to 6 months after the end of the trial, the volunteers (including male volunteers) had no plans to have children and voluntarily took effective non-drug contraceptive measures, and had no plans to donate sperm or eggs.

Exclusion Criteria:

1. Have any clinically serious disease history or are currently suffering from related diseases, including but not limited to diseases of the digestive system, cardiovascular system, respiratory system (such as asthma, etc.), urinary system, musculoskeletal system, endocrine system, neuropsychiatric system, blood system, immune system and other systems; Have any disorders such as coagulopathy (e.g. hemophilia) or a history of haemorrhagic diseases such as hemorrhoids, acute gastritis or gastric and duodenal ulcers; Patients with severe ocular diseases or acute ocular inflammation (conjunctivitis, blepharitis, keratitis, etc.), dry eye or pruritus; Have herpes virus infection;

2. Those who have participated in and used the trial drug;

3. Lactating and pregnant women, or women of childbearing age volunteers with positive blood pregnancy test;

4. Had a history of dizzy with needles and blood; Or patients with orthostatic hypotension;

5. Patients who had used immunosuppressant or immunopotentiator within 3 months before drug administration;

6. There are birthmarks, scars, tattoos, open wounds at the administration site (around the umbilical cord);

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• MG-K10 humanized monoclonal antibody injection (prefilled syringe)
MG-K10 Humanized Monoclonal Antibody Injection
• MG-K10 humanized monoclonal antibody injection(Penicillin bottle)
MG-K10 humanized monoclonal antibody injection (single injection)

Locations

Country	Name	City	State
China	The Second Affiliated Hospital of Anhui Medical University	Hefei	Anhui

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Mabgeek Biotech.Co.Ltd	The Second Hospital of Anhui Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic: the maximum concentration (Cmax)	Concentration and exposure	57 days
Primary	Pharmacokinetic: area under the curve of o~t	Concentration and exposure	57 days
Primary	Pharmacokinetic: area under the curve of o~8	Concentration and exposure	57 days
Secondary	Safety evaluation index	Any adverse medical events that occur during a clinical study	57 days